Osteoporosis: high-dose teriparatide combo rapidly increases BMD

  • Lancet Diabetes Endocrinol.

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • High-dose (40 μg) vs standard dose (20 μg) teriparatide with denosumab delivered large and rapid BMD increases in a phase 4 trial of postmenopausal patients with osteoporosis.

Why this matters

  • Increases were larger than observed with other drugs, alone or in combination, suggesting that the therapeutic regimen provides a way to "restore skeletal integrity" in osteoporosis, according to authors.

Study design

  • DATA-HD (n=69) was a randomised controlled trial comparing high-dose or standard dose teriparatide subcutaneously (SC) daily for 9 months; at 3 months, both groups started 60 mg denosumab every 6 months SC for 12 months.
  • Funding: NIH; Dart Foundation.

Key results

  • At 15 months, the high-dose vs standard dose group had greater:
    • Mean spine areal BMD (aBMD): 17.5% vs 9.5% increase from baseline (difference, 8.1%; P<.0001>
    • Mean femoral neck aBMD: 6.8% vs 4.3% (difference, 2.5%; P=.04).
    • Mean total hip aBMD: 6.1% vs 3.9% (difference, 2.2%; P<.0001>
  • The high-dose (vs standard dose) group had similar total adverse events (AEs: 78% and 77%), but fewer serious AEs (5% vs 18%).
  • Most frequent AEs with high-dose teriparatide were fatigue (38%), nausea (43%), and joint pain (46%).
    • Joint pain (38%), muscle cramp (38%), and fatigue (31%) were most common with standard dosing.

Limitations

  • Open-label, single-centre study.